Sercan Aksoy

Окончил медицинский факультет Университета Хаджеттепе в 1997 году. Прошёл ординатуру по внутренним болезням и субспециализацию по медицинской онкологии на кафедре внутренних болезней медицинского факультета Университета Хаджеттепе. В 2009 году стал доцентом, в 2014 году — профессором.

Получил поощрительную премию ТЮБИТАК в области биологии среди лицеев (1990), в 2006 году — премии за устный доклад и постер на 1-м Конгрессе по медицинской онкологии. Получил премию молодого участника на 33-м Национальном конгрессе по гематологии (2007), в 2008 году — премии за устный доклад и постер на 2-м Конгрессе по медицинской онкологии, а в 2009 году на 6-м Конгрессе по медицинской онкологии — премию д-ра Мустафы Самура за лучший устный доклад. Имеет более 150 публикаций в различных международных журналах.
Занимается лечением опухолей головы и шеи и молочной железы.

1. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group studyMuğlu H., SÜNGER E., Özkan O., ŞAHİN T. K., Köylü B., Helvacı K., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
2. Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerSahin T. K., Orhan C., Ozercan I. H., Muglu H., Er B., Akyildiz A., et al.Experimental Hematology and Oncology, cilt.15, sa.1, 2026 (SCI-Expanded, Scopus)
3. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective studyOruç A., Deliktaş Onur İ., Uyar G. C., Şahin T. K., Tünbekici S., ARSLAN KAPUCİ A., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
4. Digital multiplex ligation-dependent probe amplification identifies exon-level copy number variants in patients with suspected hereditary cancer and negative next-generation sequencing resultsDURMAZ ÖZDİNÇ C. D., Bulut N. S., ERKAN KOLAÇ D. D., KERTMEN N., AKÇİN Ö. Ç., DİZDAR Ö., et al.Molecular Biology Reports, cilt.53, sa.1, 2026 (SCI-Expanded, Scopus)
5. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark AnalysisTaban H., AKSOY S., Evlendi Y., AKTAŞ B. Y., Aslan F., ERMAN M.Journal of Clinical Medicine, cilt.15, sa.18, 2026 (SCI-Expanded, Scopus)
6. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective StudyTaban H., AKSOY S., GÜVEN D. C., AKTAŞ B. Y., Yılmaz F., Aslan F., et al.Medicina (Lithuania), cilt.62, sa.9, 2026 (SCI-Expanded, Scopus)
7. Physical activity and exercise beliefs of patients with cancer during chemotherapy: relation with social participation and quality of life levelGumus O., Ocag O., AKSOY S., YILDIZ KABAK V.Supportive Care in Cancer, cilt.34, sa.7, 2026 (SCI-Expanded, Scopus)
8. Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory BiomarkersŞahin G., Dişli A. K., ŞİRVAN F., Mıdık M. M., Boyraz N. E., Belen O., et al.Medicina (Lithuania), cilt.62, sa.7, 2026 (SCI-Expanded, Scopus)
9. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeyyar M., Kalem A., SALİ M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.Current Oncology, cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)
10. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint InhibitorsŞahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.Journal of Oncological Science, cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)
11. High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patientsTelli T., TUNCEL M., KARABULUT E., AKSOY S., ERMAN M., AKDOĞAN B., et al.Urologic Oncology: Seminars and Original Investigations, cilt.44, sa.4, 2026 (SCI-Expanded, Scopus)
12. Survival Outcomes and Prognostic Factors in Head and Neck Adenoid Cystic Carcinoma Following Curative SurgeryBölek H., Kayaalp M., Şahi̇n T. K., DOĞAN O. T., YÜKSEL S., DURU BİRGİ S., et al.Journal of Oncological Science, cilt.12, sa.1, ss.51-58, 2026 (Scopus, TRDizin)
13. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology GroupTunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.International Journal of Cancer, cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)
14. Immunotherapy in locally advanced head and neck squamous cell carcinoma: The current status and future outlookKöylü B., Selçukbiricik F., AKSOY S., GÜVEN D. C.Critical Reviews in Oncology/Hematology, cilt.219, 2026 (SCI-Expanded, Scopus)
15. Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort StudyKarahan L., Akyildiz A., Sahin T. K., Batu M. A., ERŞAN Y. Ç., ONUR M. R., et al.Journal of Clinical Medicine, cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)
16. Elacestrant in metastatic breast cancer: current advancements and future perspectivesSahin T. K., Makasheva B., GÜVEN D. C., AKSOY S., Di Lauro V., Rizzo A.Expert Review of Anticancer Therapy, cilt.26, sa.6, ss.697-706, 2026 (SCI-Expanded, Scopus)
17. Prognostic significance of ductal carcinoma in situ coexisting with invasive ductal carcinoma: Biological behavior, immune response and survival outcomesFedai N. K., Koc I., KAVGACI G., ÜNER M., ÜNER A., AKSOY S., et al.Molecular and Clinical Oncology, cilt.24, sa.1, 2026 (ESCI, Scopus)
18. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabGüren A. K., DEMİRCAN N. C., GÜMÜŞAY Ö., Şimşek E. T., Kemik F., KARAOĞLU Ç., et al.Immunotherapy, cilt.18, sa.4, ss.317-326, 2026 (SCI-Expanded, Scopus)
19. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studySahin T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.Therapeutic Advances in Medical Oncology, cilt.18, 2026 (SCI-Expanded, Scopus)
20. Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLicitra L., Tahara M., Harrington K., Olivera Hurtado de Mendoza M., Guo Y., AKSOY S., et al.Journal of Clinical Oncology, 2026 (SCI-Expanded, Scopus)
21. Predictors of Chemotherapy Induced Neutropenia in Patients with Breast CancerSari A., AKSOY S., Ascioglu S.Journal of oncological sciences, cilt.11, sa.2, ss.89-95, 2025 (Scopus, TRDizin)
22. Bone-modifying agents and survival in patients treated with immune checkpoint inhibitorsBAŞ O., GÜNER N. İ., Tokatlı M., GÜDÜK N., ŞAHİN T. K., YALÇIN N., et al.Journal of medicine and palliative care (Online), cilt.6, 2025 (TRDizin)
23. Gastrointestinal sistem maligniteli hastalarda demir eksikliği ve kronik hastalık anemisi ayırıcı tanısında soluble transferrin reseptör düzeylerinin yeriPerkin P., Zeynelgil E., BAKIR F., Civelek B., AKSOY S., Abaylı E.Turkish Journal of Clinics and Laboratory, cilt.16, sa.2, ss.294-301, 2025 (TRDizin)
24. Fibrosis- 4 index and survival in early breast cancer patientsBas O., TOKATLI M., GÜDÜK N., Karahan L., Sahin T. K., AKSOY S.Acta Medica, cilt.56, sa.2, ss.70-75, 2025 (TRDizin)
25. Does Adding Chemotherapy to Radiotherapy Improve Outcomes in Stage II Nasopharyngeal Carcinoma?KAHVECIOĞLU A., YILMAZ M. T., MOHAMMADIPOUR S., SARI S. Y., CENGİZ M., GÜLLÜ İ., et al.Türk Onkoloji Dergisi, cilt.40, sa.2, ss.112-119, 2025 (ESCI, Scopus, TRDizin)
26. Breast Radiotherapy: A Potential Risk Factor for Resistant Clone Development in Patients with Brain MetastasisYildirim H. c., Kavgacı G., Evlendi Y., CHALABIYEV E., Guven D. C., Dizdar O., et al.Journal of oncological sciences, cilt.11, sa.1, ss.7-13, 2025 (Scopus, TRDizin)
27. Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center ExperienceBAŞ O., Tokatli M., Guduk N., Erdogan D., Boyraz N. E., Cengelci C., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.8, 2025 (SCI-Expanded, Scopus)
28. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancerSahin T. K., Rizzo A., GÜVEN D. C., AKSOY S.CANCER TREATMENT REVIEWS, cilt.135, 2025 (SCI-Expanded, Scopus)
29. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with CancerBAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.5, 2025 (SCI-Expanded, Scopus)
30. Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitorsBAŞ O., Tokatli M., Savkliyildiz M., Yazarkan Y., Guduk N., Kilinc C., et al.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.4, ss.405-409, 2025 (SCI-Expanded, Scopus)
31. Ribociclib-induced autoimmune-like hepatitis: a case reportKAVGACI G., ŞAHİN T. K., SÖKMENSÜER C., BALABAN H. Y., AKSOY S.JOURNAL OF CHEMOTHERAPY, cilt.37, sa.8, ss.741-746, 2025 (SCI-Expanded, Scopus)
32. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitorsŞAHİN T. K., AKSOY S., GÜVEN D. C.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.5, ss.471-484, 2025 (SCI-Expanded, Scopus)
33. The association between HALP score and survival in patients treated with immune checkpoint inhibitorsŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.1, ss.81-89, 2025 (SCI-Expanded, Scopus)
34. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitorsŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, cilt.25, sa.4, ss.129-137, 2025 (SCI-Expanded, Scopus)
35. The perspectives and knowledge of patients with cancer on mpox and mpox vaccination: a cross-sectional studyŞAHİN T. K., KAYGUSUZ Y., Icli M. C., AKSOY S., GÜVEN D. C.CURRENT MEDICAL RESEARCH AND OPINION, cilt.41, sa.1, ss.83-91, 2025 (SCI-Expanded, Scopus)
36. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) studyYILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sanci P. C., Guliyev M., et al.Journal of Chemotherapy, cilt.37, sa.1, ss.69-75, 2025 (SCI-Expanded, Scopus)
37. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)
38. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerYILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.MEDICINE, cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)
39. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab EmtansineŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.PHARMACEUTICALS, cilt.17, sa.7, 2024 (SCI-Expanded, Scopus)
40. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyCho B. C., Brana I., Cirauqui B., AKSOY S., Couture F., Hong R., et al.BMC CANCER, cilt.23, sa.SUPPL 1, 2024 (SCI-Expanded, Scopus)
41. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitorsKAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.SUPPORTIVE CARE IN CANCER, cilt.32, sa.7, 2024 (SCI-Expanded, Scopus)
42. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancerSaatci O., Alam R., Huynh-Dam K., Isik A., ÜNER M., BELDER N., et al.CELL DEATH & DISEASE, cilt.15, sa.6, 2024 (SCI-Expanded, Scopus)
43. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-AnalysisSahin T. K., Rizzo A., AKSOY S., Guven D. C.CANCERS, cilt.16, sa.10, 2024 (SCI-Expanded, Scopus)
44. The Impact of Concurrent Chemotherapy on Stage II Nasopharyngeal CarcinomaYilmaz M. T., KAHVECİOĞLU A., Mohammadipour S., CENGİZ M., Gullu I., AKSOY S., et al.RADIOTHERAPY AND ONCOLOGY, 2024 (SCI-Expanded, Scopus)
45. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast CancerGedik M. E., Saatci O., Oberholtzer N., ÜNER M., Caliskan O. A., Cetin M., et al.CANCER RESEARCH, cilt.84, sa.9, ss.1475-1490, 2024 (SCI-Expanded, Scopus)
46. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialMachiels J., Tao Y., Licitra L., Burtness B., Tahara M., Rischin D., et al.The Lancet Oncology, cilt.25, sa.5, ss.572-587, 2024 (SCI-Expanded, Scopus)
47. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYBalmaña J., Fasching P. A., Couch F. J., Delaloge S., Labidi-Galy I., O’Shaughnessy J., et al.Breast Cancer Research and Treatment, cilt.204, sa.2, ss.237-248, 2024 (SCI-Expanded, Scopus)
48. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) studyYıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.International Journal of Clinical Oncology, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)
49. Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancerKAVGACI G., ŞAHİN T. K., Muderrisoglu T., Ileri S., GÜVEN D. C., AKSOY S.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.24, sa.12, ss.1319-1326, 2024 (SCI-Expanded, Scopus)
50. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-AnalysisGÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.Laryngoscope, cilt.134, sa.1, ss.7-17, 2024 (SCI-Expanded, Scopus)
51. Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancerSaatci O., Cetin M., ÜNER M., Tokat U. M., Chatzistamou I., Ersan P. G., et al.Nature Communications, cilt.14, sa.1, 2023 (SCI-Expanded, Scopus)
52. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency AnemiaAKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.Current Oncology, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
53. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with NivolumabYILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.Journal of Immunotherapy and Precision Oncology, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
54. Molecularly imprinted electrochemical sensor for the selective and sensitive determination of octreotide in cancer patient plasma sampleOzkan E., Ozcelikay G., Gök Topak E. D., NEMUTLU E., ÖZKAN S. A., DİZDAR Ö., et al.Talanta, cilt.263, 2023 (SCI-Expanded, Scopus)
55. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancerŞener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.Strahlentherapie und Onkologie, cilt.199, sa.8, ss.761-772, 2023 (SCI-Expanded, Scopus)
56. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectivesERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.European Archives of Oto-Rhino-Laryngology, cilt.280, sa.8, ss.3541-3556, 2023 (SCI-Expanded, Scopus)
57. GLIM criteria as a valid tool for nutrition assessment and mortality prediction in treatment-naïve patients with cancerBALCI C., Tufan G., Özdemir N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., et al.Nutrition in Clinical Practice, cilt.38, sa.4, ss.798-806, 2023 (SCI-Expanded, Scopus)
58. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort studyGÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)
59. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitorsGÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.Anti-Cancer Drugs, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
60. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialAndré F., Hee Park Y., Kim S., Takano T., Im S., Borges G., et al.The Lancet, cilt.401, sa.10390, ss.1773-1785, 2023 (SCI-Expanded, Scopus)

All 106 on AVESİS →

1. Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC studyPernas S., Hinojo C., Pascual J., AKSOY S., Clack G., McIntosh S.Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
3. Reirradiation with Stereotactic Ablative Radiotherapy in Recurrent Nasopharyngeal CarcinomaYilmaz M. T., YİĞİT E., KAHVECİOĞLU A., YEDEKÇİ F. Y., YÜCE SARI S., CENGİZ M., et al.9th International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO), Barcelona, İspanya, 21 - 23 Mart 2024, (Özet Bildiri)
4. Reirradiation With Stereotactic Ablative Radiotherapy In Recurrent Head And Neck CancersYİĞİT E., Yilmaz M. T., KAHVECİOĞLU A., YEDEKÇİ F. Y., YÜCE SARI S., CENGİZ M., et al.9th International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO), Barcelona, İspanya, 21 - 23 Mart 2024, (Özet Bildiri)
5. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyGÜVEN D. C., Incesu F. G. G., Yildirim H. C., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, cilt.33, (Özet Bildiri)
6. KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinomaSiu L. L., Licitra L., Tao Y. G., Yen C., Rischin D., Waldron J., et al.Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, Amerika Birleşik Devletleri, 14 - 18 Nisan 2018, cilt.78, (Özet Bildiri)
7. Baş-Boyun Melanomlarında Radyoterapi SonuçlarımızYÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T., AKSOY S., GÜLLÜ İ. H., et al.13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Türkiye, 27 Nisan - 01 Mayıs 2018, (Tam Metin Bildiri)
8. Metastatik NUT Midline Karsinomunda İmmünoterapi ve Reirradyasyon: Vaka Sunumu.ELMALI DOĞAN A., YILMAZ M. T., AKSOY S., YÜCE SARI S., ÖZYİĞİT G., YAZICI G.13.Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 27 Nisan - 01 Mayıs 2018, (Tam Metin Bildiri)
9. GERİATRİK POPÜLASYONDAKİ YENİ TANIONKOLOJİK VAKALARDA MALNUTRİSYON VESARKOPENİ SIKLIĞI: ÇOK MERKEZLİ-KESİTSELÇALIŞMABALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., et al.11. Akademik Geriatri Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2018, (Özet Bildiri)
10. Bağışıklık sistemi baskılanmış hastalarda Microsporidia ve fırsatçı bağırsak parazitlerinin varlığının araştırılmasıKaya F., İNKAYA A. Ç., AKSOY S., ABBASOĞLU O., ERTENLİ A. İ., BÜYÜKAŞIK Y., et al.4. Ulusal Klinik Mikrobiyoloji Kongresi, Türkiye, 8 - 12 Kasım 2017, (Özet Bildiri)
11. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİKERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
12. Role of glutamine for preventing oxaliplatin induced peripheralneuropathy GELUPO results of randomized open label phaseII triaYazıcı O., Titiz A., ÖZDEMİR N., AKSOY S., ŞENDUR M. A. N., Arlı B., et al.ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
13. Impact of vitamin D3 replacement therapy on clinicaloutcomes and survival rates in patients with early stage breastcancerYAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., ZENGİN N., ALTUNDAĞ M. K.ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
14. Survival and Larynx Preservation Rates after Definitive Radiotherapy A Single Center ExperienceCENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., et al.ECHNO 2016, Budapest, Macaristan, 7 - 10 Eylül 2016, (Özet Bildiri)
15. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcomaATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
16. Serological Detection of Strongyloides strecoralis infection in immunosupressed patients Hacettepe ExperienceKaya F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., et al.Acta Microbiologica Helenica (9th Balkan Congress of Microbiology), 22 - 24 Ekim 2015
17. SEROLOGICAL DETECTION OF STRONGYLOIDES STERCORALIS INFECTION IN IMMUNOSUPRESSED PATIENTS: HACETTEPE EXPERIENCEDEMİREL KAYA F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., et al.9TH BALKAN CONGRESS OF MICROBIOLOGY, SELANİK, Yunanistan, 22 - 24 Ekim 2015, (Özet Bildiri)
18. Tumor locations significantly affect disease free survival and overall survivalBUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
19. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R SeverALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
20. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in ratsAksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
21. Predictors of outcome in patients with advanced nonseminamatous germ cell testicular tumors.Yetisyigit T., Babacan N., Urun Y., Seber S., Arpaci E., Clhan S., et al.50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
22. Comparison of long-term cardiac effects of 9-and 52-week trastuzumab in HER2-positive early breast cancer.Sendur M. A. N., Aksoy S., Ozdemir N., Yorgun H., Yilmaz F. M., Yazici O., et al.50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
23. Retrospective review of modified dose docetaxel, cisplatin, and 5-flourouracil (DCF) for the treatment of first-line metastatic gastric carcinomas.Ozdemir N., Aksoy S., Eren T., Abali H., Oksuzoglu O. B., Zengin N.49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
24. Clinicopathologic characteristics of pure papillary breast carcinomaTurkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
25. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., et al.49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
26. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.Sendur M. A. N., Aksoy S., Yaman S., Kos F. T., Arik Z., Civelek B., et al.48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
27. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphomaKilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., et al.30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.202, (Özet Bildiri)
28. Overcoming chemotherapy resistance in triple negative breast cancer via targeting lysyl oxidase (LOX)Saatçi Ö., Akbulut Ö., Rezaeain A., Banister C., Sikirzhytski V., AKSOY S., et al.
29. Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients.Özer Ö., NEMUTLU E., Eylem C. C., KIR S., REÇBER T., Aktas B. Y., et al.
30. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.Cem O., Sedef A. M., Kose F., Oymak E., Guler O. C., Sumbul A. T., et al.
31. The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.Yildirim B., Cem O., Kose F., Oymak E., Sedef A. M., Besen A. A., et al.
32. Trace-Level Determination of 2-Amino Adipic Acid by LC-ESI-MS/MS for Early Diagnosis of Breast CancerREÇBER T., AKSOY S., NEMUTLU E., KIR S.
33. Mass Spectrometry Based Targeted and Untargeted Metabolomic Analysis for Early Diagnosis of Breast Cancer Using LC-ESI-qTOF-MS and LC-ESI-MS/MSREÇBER T., AKSOY S., BEKSAÇ K., CENNET Ö., KAYNAROĞLU Z. V., NEMUTLU E., et al.
34. Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S., GÜLLÜ İ. H., et al.
35. High Prevelance of Malnutrition and Sarcopenia in Newly Diagnosed Cancer Patients in Turkey: Multicenter, Cross Sectional StudyBALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., et al.
36. Effect of using different antihypertensive drugs ondemographic and clinico pathological characteristics ofbreast cancerŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., AKINCI M. B., ŞENER DEDE D., et al.
37. Effect of body mass index in the outcome of stage I III triplenegative breast cancerŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., ZENGİN N., ALTUNDAĞ M. K.
38. Effect of polypharmacy on treatment preferences andoutcome in older breast cancer patientsŞENDUR M. A. N., SILAY K., AKSOY S., Özbek S., ÖZDEMİR N., ALTUNDAĞ M. K.
39. Effect of using different antidiabetic drugs on demographicand clinico pathological characteristics of breast cancerŞENDUR M. A. N., AKSOY S., Yazıcı O., ÖZDEMİR N., ŞENER DEDE D., AKINCI M. B., et al.
40. Comparison of clinical outcomes in patents with early stage ER PR HER2 breast cancer patients with triple negativesErdem G. U., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Doğan M., ZENGİN N., et al.
41. Intravenous ferric carboxymaltose treatment in cancer patientsASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
42. The impact of the total size of lesions in multifocal multicentric breast cancer on survivalKarakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.
43. Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective studyDEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., et al.
44. Study of the impact of Charlson comorbidity index on the efficacy of aromatase inhibitors in patients with hormone receptor positive postmenopausal breast cancerŞENDUR M. A. N., AKSOY S., SILAY K., AKINCI M. B., ÖZDEMİR N., YAZICI O., et al.
45. Neuroendocrine breast cancer A single center experienceTAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.
46. Brain specific progression free survival bsPFS according to breast cancer subtypes in patients with brain metastasesARSLAN Ç., YAZICI O., AKSOY S., ALTUNDAĞ M. K.
47. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancerAteş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
48. The role of the gastrectomy on survival in metastatic gastric cancer patients: A multicenter study of Anatolian Society of Medical Oncology (ASMO)Yazici O., Ozdemir N., Duran A. O., Menekse S., Sendur M. A. N., Karaca H., et al.
49. Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass indexAltundag K., Sendur M. A. N., AKSOY S., BABACAN T., Ozisik Y.
50. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.
51. Effect of body mass index on metastatic pattern in early breast cancer patients.Yazici O., Aksoy S., Sendur M. A. N., Ozdemir N., Zengin N., Altundag K.
52. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.
53. Metformin in diabetic pancreatic cancer patients: Benefit or not-Multicenter experience.Esbah O., Oksuzoglu B., Eren T., Helvaci K., Guler T., Duran A. O., et al.
54. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., et al.
55. Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.Altundag K., Aksoy S., Sendur M. A. N., Guler E. N., Gullu I. H., Ozisik Y. Y.
56. Retrospective analysis of 178 patients with stage I rectum cancer.Cihan S., Ozdemir N., Urakci Z., Kucukoner M., Dane F., Yazilitas D., et al.
57. Inflammatory markers in metastatic breast cancer.Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., et al.
58. Demographic and clinicopathologic characteristics in patients with invasive breast cancer receiving metformin.Aksoy S., Sendur M. A. N., Altundag K.
59. The number of metastatic lymph node in N3M0 breast cancer and influence on survival.Solak M., Turkoz F. P., Keskin O., Petekkaya H., Sarici S. F., Babacan T., et al.
60. Inflammatory markers in early-stage breast cancer.Petekkaya H., Aksoy S., Gecmez G., Kulahcioglu E., Okoh A. K., Isler D. C., et al.

All 67 on AVESİS →

1. Systemic Therapies in the Managementof Testicular CancersŞENDUR M. A. N., AKSOY S.Principles and Practice of UrooncologyRadiotherapy, Surgery and SystemicTherapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editör, Springer, 2017
2. Targeted Therapies and Immunotherapy in Bladder CancerŞENDUR M. A. N., AKSOY S.Principles and Practice of UrooncologyRadiotherapy, Surgery and SystemicTherapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editör, Springer, ss.141-152, 2017
3. Kanser ve Kalp YetmezliğiŞENDUR M. A. N., AKSOY S.Kalp Yetmezliği Cep Kitabı, Prof. Dr. Ali Oto, Prof. Dr. Barış Kaya, Prof Dr. Kudret Aytemir, Editör, Erkem Tıbbi Yayıncılık, 2016
4. Systemic Therapies in Malignant Pleural MesotheliomaYazıcı O., AKSOY S.Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gokhan Ozyigit, Ugur Selek, Erkan Topkan, Editör, Springer, ss.469-481, 2016
5. Current Systemic Therapy Options for Head and Neck CancerŞENDUR M. A. N., AKSOY S.